School nurses are encouraged to take advantage of this free educational webinar, Confidence in the Classroom, that shares info on how to help students with epilepsy manage episodes of frequent seizures at school.
See Important Safety Information below.
Click to Register Today
Confidence in the Classroom
Did you miss the popular webinar, Confidence in the Classroom? Now’s your chance to join Dr. Lewis and Dr. Schuele. This free webinar is designed to support you in helping your students with epilepsy manage episodes of frequent seizures at school.
Register today to learn more about VALTOCO® (diazepam nasal spray)––the only nasal spray seizure rescue for students with epilepsy ages 6 and older.1
Webinar Details
Secure your spot for this exclusive presentation, Confidence in the Classroom, by selecting your preferred date and time:
Dalila Watford Lewis, MD, FAAP
Associate Professor, Department of Pediatrics
Division Chief, Pediatric Neurology
Program Director, Child Neurology Residency Program
Medical University of South Carolina
Charleston, SC
Stephan Ulrich Schuele, MD, MPH
Professor of Neurology and Physical Medicine & Rehabilitation
Northwestern University Feinberg School of Medicine
Medical Director
Northwestern Memorial Hospital
Chicago, IL
After registering, you will receive a confirmation email with important log-in information.
This webinar features insights on:
• Managing episodes of frequent seizures in the school setting
• Role of seizure action plans and medication
• Updated VALTOCO long-term safety clinical data
• New resources for school nurses
Advocate for THE COMPASSIONATE CHOICE for your students.2
IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING
Indication
VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.
IMPORTANT SAFETY INFORMATION
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS
• Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
• The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death.
• The continued use of benzodiazepines may lead to clinically significant physical dependence. Although VALTOCO is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of VALTOCO may precipitate acute withdrawal reactions, which can be life-threatening.
Adverse Reactions
The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.
Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.
To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1‑866‑696‑3873 or FDA at 1‑800‑FDA‑1088 (www.fda.gov/medwatch).
Please see full Prescribing Information, including Boxed Warning.
References: 1. VALTOCO® (diazepam nasal spray) Prescribing Information. Neurelis, Inc. 2. Woodcock J: on behalf of Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). Petition Response Letter from FDA CDER to Arent Fox LLP. Docket No. FDA-2019-P-5121. https://www.regulations.gov/document/FDA-2019-P-5121-0011. Published January 10, 2020. Accessed January 10, 2023.
For more on our series on rescue medications, visit: https://livingwellwithepilepsy.com/category/aboutepilepsy/rescue-medication
Leave a Reply